Literature DB >> 20600548

PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals.

Frédéric Y Bois1, Masoud Jamei, Harvey J Clewell.   

Abstract

Generic PBPK models, applicable to a large number of substances, coupled to parameter databases and QSAR modules, are now available for predictive modelling of inter-individual variability in the absorption, distribution, metabolism and excretion of environmental chemicals. When needed, Markov chain Monte Carlo methods and multilevel population models can be jointly used for a Bayesian calibration of a PBPK model, to improve our understanding of the determinants of population heterogeneity and differential susceptibility. This article reviews those developments and illustrates them with recent applications to environmentally relevant questions.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20600548     DOI: 10.1016/j.tox.2010.06.007

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  46 in total

1.  A physiologically based pharmacokinetic model for capreomycin.

Authors:  B Reisfeld; C P Metzler; M A Lyons; A N Mayeno; E J Brooks; M A Degroote
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

3.  Impact of Nonalcoholic Fatty Liver Disease on Toxicokinetics of Tetrachloroethylene in Mice.

Authors:  Joseph A Cichocki; Shinji Furuya; Kranti Konganti; Yu-Syuan Luo; Thomas J McDonald; Yasuhiro Iwata; Weihsueh A Chiu; David W Threadgill; Igor P Pogribny; Ivan Rusyn
Journal:  J Pharmacol Exp Ther       Date:  2017-02-01       Impact factor: 4.030

Review 4.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

5.  Probabilistic risk assessment of gold nanoparticles after intravenous administration by integrating in vitro and in vivo toxicity with physiologically based pharmacokinetic modeling.

Authors:  Yi-Hsien Cheng; Jim E Riviere; Nancy A Monteiro-Riviere; Zhoumeng Lin
Journal:  Nanotoxicology       Date:  2018-04-14       Impact factor: 5.913

6.  Population pharmacokinetic reanalysis of a Diazepam PBPK model: a comparison of Stan and GNU MCSim.

Authors:  Periklis Tsiros; Frederic Y Bois; Aristides Dokoumetzidis; Georgia Tsiliki; Haralambos Sarimveis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-04       Impact factor: 2.745

Review 7.  Use of Exposomic Methods Incorporating Sensors in Environmental Epidemiology.

Authors:  Brett T Doherty; Jeremy P Koelmel; Elizabeth Z Lin; Megan E Romano; Krystal J Godri Pollitt
Journal:  Curr Environ Health Rep       Date:  2021-02-10

8.  Recommendations for biomonitoring of emergency responders: focus on occupational health investigations and occupational health research.

Authors:  John A Decker; D Gayle DeBord; Bruce Bernard; G Scott Dotson; John Halpin; Cynthia J Hines; Max Kiefer; Kyle Myers; Elena Page; Paul Schulte; John Snawder
Journal:  Mil Med       Date:  2013-01       Impact factor: 1.437

Review 9.  Innovative clinical trial design for pediatric therapeutics.

Authors:  Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

Review 10.  Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.

Authors:  Yu-Mei Tan; Rachel R Worley; Jeremy A Leonard; Jeffrey W Fisher
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.